Microfluidic 3D-printed MSC-laden bioactive hydrogel for intrauterine adhesion prevention and endometrial regeneration.
Song Y., Ma R., Yi B., Zhou Q., Li X., Zhou Y.
Laboratory Study, published in Mater Today Bio (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Mater Today Bio (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41560816
- PMCID
- PMC12813364
- DOI
- 10.1016/j.mtbio.2025.102742
Abstract (original English)
Increasing occurrence of intrauterine adhesion (IUA) is a serious threat to the reproductive health of women in recent years. However, treatment options remain limited. Mesenchymal stem cell (MSC)-based therapies have shown a promising regenerative capacity of injured endometrium but have limited effectiveness by the low survival duration of transplanted cells. Herein, we present a bioactive hydrogel scaffold loaded with adipose tissue-derived MSC (AT-MSC) by using a three-dimensional (3D) bioprinting technology, which combines the characteristics of the synthetic thermos-responsive material PF-127 and the natural-derived, photo-polymerizable material GelMA. The composite hydrogel scaffold shows enhanced mechanical as well as biocompatibility. In addition, the porous structure endows the 3D-printed scaffold with a favorable growing environment for MSC and increase the retention rate of cells. Finally, the dual repair effects of the MSC-laden gel scaffold on endometrial damage and regeneration are validated in a rat IUA model. This study demonstrates that the composite system could improve neovascularization, increase number of glands, and ameliorate fibrotic formation of endometrium. Thus, it is believed that such bioactive MSC-loaded scaffold is a promising candidate for prevention of IUA with reliable endometrial regeneration properties.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.